Pyrolytic characterization of humic acids in relation to carbon sequestration mechanisms in representative soils from the basque country (Northern Spain)

Comunicación y póster presentados al citado simposio, celebrado del 17-20 de septiembre, 2002, en Leoben (Austria).Curie-Point analytical pyrolysis was used for the assessment of soil organic matter accumulation processes in representative ecosystems from the Basque Country (Northem Spain). The aim of the study is to identify the main mechanisms of carbon sequestration by carrying out a semiquantitative appraisal of biogeochemical processes ranging from selective preservation of plant macromolecular material to complex processes involving extensive depolymerization of plant-inherited constituents followed by synthesis of humic-type substances.Peer reviewe

Infección con el virus de la inmunodeficiencia felina: desarrollo y aplicación de una técnica de doble reacción en cadena de la polimerasa (PRC) para el diagnóstico

A Nested PCR technique for direct identification of Feline Immunodeficiency Virus (FIV) was developed. Two methods for proviral DNA extraction and two pairs of primers were evaluated. The method for amplification was standardized and its specificity was determined by the restriction endonucleases digestion of PCR products. Antibodies specific to FIV were determined using a commercial kit. Thirty heparinized blood samples obtained from cats with and without clinical signs consistent with FIV infection were analyzed. In 17 of the samples antibodies specific to FIV and proviral DNA were detected. The PCR technique proved sensitive and specific. It could be useful in the presence of doubtful serologic results and to detect provirus in cats with recent infections.Se desarrolló una técnica de doble reacción en cadena de la polimerasa ( Nested PCR ) para la detección directa del virus de la Inmunodeficiencia Felina (VIF). Se evaluaron dos métodos de extracción de DNA proviral y cuatro pares de cebadores. Se estandarizó el método de amplificación y la especificidad fue determinada por digestión de los productos de PCR con enzimas de restricción. La determinación de anticuerpos se realizó con un equipo comercial. Se trabajó con 30 muestras de sangre heparinizada provenientes de gatos con y sin signos clínicos compatibles con la infección con VIF. En 17 de las muestras examinadas se detectaron anticuerpos específicos contra VIF y DNA proviral. La técnica de PCR desarrollada resultó sensible y específica y podría ser utilizada cuando se presentaran resultados serológicos dudosos o para la detección del provirus en gatos con infecciones recientes

Habitat quality affects the condition of Luciobarbus sclateri in the Guadiamar River (SW Iberian Peninsula): Effects of disturbances by the toxic spill of the Aznalcóllar mine

This study analyzes the somatic condition of southern Iberian barbel Luciobarbus sclateri (Günther, 1868) in the Guadiamar River (SW Iberian Peninsula). This river was seriously affected by a toxic spill of about 4 million cubic meters of acidic water and 2 million cubic meters of mud rich in heavy metals. Once the spill removal works concluded, sites affected and unaffected by the accident were sampled to study its effects on the fish fauna. The ecological variables registered were related to water quality, physical state of reaches, ecological quality, resources exploited by fish, and potential intra-specific interactions. From an initial 15 ecological variables, seasonal water flow and pH explained most of the variation in barbel condition. This study shows that the Guadiamar River, 56 months after the accident, is still undergoing a recovery process where, beyond ecological variables, proximity to the affected area is the most influential factor for fish condition. © 2012 Springer Science+Business Media B.V

Equine herpesvirus type 1 (EHV-1): restriction fragment patterns, polyacrylamide gel electrophoresis profiles and pathogenicity in baby mice

Se estudiaron siete cepas de herpesvirus equino 1 (EHV-1) aisladas en Argentina desde 1979 hasta 1996 y una cepa de referencia japonesa, analizándose los patrones de restricción del ADN, perfiles proteicos en geles de poliacrilamida (SDS-PAGE) y los biotipos, para determinar posibles diferencias entre las mismas y su correlación con la patogenicidad en el ratón. El análisis genómico con enzimas de restricción demostró que todas las cepas pertenecen al tipo 1P de EHV-1. Sólo el primer aislamiento realizado en el país (cepa SP) mostró diferencias en su patrón de restricción del ADN. Esta cepa y la cepa aislada en el año 1985 (cepa LP) presentaron además diferencias en sus perfiles proteicos. El estudio de patogenicidad en ratones indicó la presencia de tres biotipos, no encontrándose correlación con las variaciones halladas en los electroferotipos y con la sintomatología clínica en el equino.Seven strains of equine herpesvirus 1 (EHV-1) isolated in Argentina from 1979 to 1996 and reference Japanese strain, were compared by restriction fragments analysis (RFA), polyacrylamide gel electrophoresis (SDS-PAGE) and inoculation of baby mice. The RFA revealed that all EHV-1 strains belonged to genome type 1P. Only the first isolate (SP strain) showed differences. This strain and the LP strain isolated in 1985 presented a small differences for SDS-PAGE analysis. Baby mice inoculation revealed that three biotypes could be distinguished on the basis of pathogenicity. However, no strict correlation with pathogenicity in the natural host was seen.Facultad de Ciencias Veterinaria

Equine herpesvirus type 1 (EHV-1): restriction fragment patterns, polyacrylamide gel electrophoresis profiles and pathogenicity in baby mice

Se estudiaron siete cepas de herpesvirus equino 1 (EHV-1) aisladas en Argentina desde 1979 hasta 1996 y una cepa de referencia japonesa, analizándose los patrones de restricción del ADN, perfiles proteicos en geles de poliacrilamida (SDS-PAGE) y los biotipos, para determinar posibles diferencias entre las mismas y su correlación con la patogenicidad en el ratón. El análisis genómico con enzimas de restricción demostró que todas las cepas pertenecen al tipo 1P de EHV-1. Sólo el primer aislamiento realizado en el país (cepa SP) mostró diferencias en su patrón de restricción del ADN. Esta cepa y la cepa aislada en el año 1985 (cepa LP) presentaron además diferencias en sus perfiles proteicos. El estudio de patogenicidad en ratones indicó la presencia de tres biotipos, no encontrándose correlación con las variaciones halladas en los electroferotipos y con la sintomatología clínica en el equino.Seven strains of equine herpesvirus 1 (EHV-1) isolated in Argentina from 1979 to 1996 and reference Japanese strain, were compared by restriction fragments analysis (RFA), polyacrylamide gel electrophoresis (SDS-PAGE) and inoculation of baby mice. The RFA revealed that all EHV-1 strains belonged to genome type 1P. Only the first isolate (SP strain) showed differences. This strain and the LP strain isolated in 1985 presented a small differences for SDS-PAGE analysis. Baby mice inoculation revealed that three biotypes could be distinguished on the basis of pathogenicity. However, no strict correlation with pathogenicity in the natural host was seen.Facultad de Ciencias Veterinaria

Isotropic Luminosity Indicators in a Complete AGN Sample

The [O IV] 25.89 micron line has been shown to be an accurate indicator of active galactic nucleus (AGN) intrinsic luminosity in that it correlates well with hard (10-200 keV) X-ray emission. We present measurements of [O IV] for 89 Seyfert galaxies from the unbiased Revised Shapley-Ames (RSA) sample. The [O IV] luminosity distributions of obscured and unobscured Seyferts are indistinguishable, indicating that their intrinsic AGN luminosities are quite similar and that the RSA sample is well suited for tests of the unified model. In addition, we analyze several commonly used proxies for AGN luminosity, including [O III] 5007 A, 6 cm radio, and 2-10 keV X-ray emission. We find that the radio luminosity distributions of obscured and unobscured AGNs show no significant difference, indicating that radio luminosity is a useful isotropic luminosity indicator. However, the observed [O III] and 2-10 keV luminosities are systematically smaller for obscured Seyferts, indicating that they are not emitted isotropically.Comment: Updated to match version published in ApJ. 9 pages, 4 figure

Role of age and comorbidities in mortality of patients with infective endocarditis

Purpose: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. Methods: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015. Patients were stratified into three age groups:<65 years, 65 to 80 years, and = 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. Results: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 = 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients =80 years who underwent surgery were significantly lower compared with other age groups (14.3%, 65 years; 20.5%, 65-79 years; 31.3%, =80 years). In-hospital mortality was lower in the <65-year group (20.3%, <65 years;30.1%, 65-79 years;34.7%, =80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%, =80 years; p = 0.003).Independent predictors of mortality were age = 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI = 3 (HR:1.62; 95% CI:1.39–1.88), and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared, the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. Conclusion: There were no differences in the clinical presentation of IE between the groups. Age = 80 years, high comorbidity (measured by CCI), and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)